258 related articles for article (PubMed ID: 17001674)
21. Evidence of post-translational modification of the tumor suppressor maspin under oxidative stress.
Nawata S; Shi HY; Sugino N; Zhang M
Int J Mol Med; 2011 Feb; 27(2):249-54. PubMed ID: 21132260
[TBL] [Abstract][Full Text] [Related]
22. Urokinase-type plasminogen activator.
Crippa MP
Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
[TBL] [Abstract][Full Text] [Related]
23. Maspin, the molecular bridge between the plasminogen activator system and beta1 integrin that facilitates cell adhesion.
Endsley MP; Hu Y; Deng Y; He X; Warejcka DJ; Twining SS; Gonias SL; Zhang M
J Biol Chem; 2011 Jul; 286(28):24599-607. PubMed ID: 21606500
[TBL] [Abstract][Full Text] [Related]
24. The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin.
Pemberton PA; Wong DT; Gibson HL; Kiefer MC; Fitzpatrick PA; Sager R; Barr PJ
J Biol Chem; 1995 Jun; 270(26):15832-7. PubMed ID: 7797587
[TBL] [Abstract][Full Text] [Related]
25. Maspin plays an essential role in early embryonic development.
Gao F; Shi HY; Daughty C; Cella N; Zhang M
Development; 2004 Apr; 131(7):1479-89. PubMed ID: 14985257
[TBL] [Abstract][Full Text] [Related]
26. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors.
Schwarz S; Ettl T; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
Oral Oncol; 2008 Jun; 44(6):563-70. PubMed ID: 17936671
[TBL] [Abstract][Full Text] [Related]
27. Maspin inhibits cell migration in the absence of protease inhibitory activity.
Bass R; Fernández AM; Ellis V
J Biol Chem; 2002 Dec; 277(49):46845-8. PubMed ID: 12384513
[TBL] [Abstract][Full Text] [Related]
28. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
29. Maspin polymorphism associated with apoptosis susceptibility and in vivo tumorigenesis.
Jang HL; Nam E; Lee KH; Yeom S; Son HJ; Park C
Int J Mol Med; 2008 Sep; 22(3):333-8. PubMed ID: 18698492
[TBL] [Abstract][Full Text] [Related]
30. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy.
Mazar AP
Clin Cancer Res; 2008 Sep; 14(18):5649-55. PubMed ID: 18794071
[TBL] [Abstract][Full Text] [Related]
31. Focused PCR screen reveals p53 dependence of nitric oxide-induced apoptosis and up-regulation of maspin and plasminogen activator inhibitor-1 in tumor cells.
Lim S; Hung AC; Porter AG
Mol Cancer Res; 2009 Jan; 7(1):55-66. PubMed ID: 19147537
[TBL] [Abstract][Full Text] [Related]
32. Paradoxical expression of maspin in gastric carcinomas: correlation with carcinogenesis and progression.
Yu M; Zheng H; Tsuneyama K; Takahashi H; Nomoto K; Xu H; Takano Y
Hum Pathol; 2007 Aug; 38(8):1248-55. PubMed ID: 17490717
[TBL] [Abstract][Full Text] [Related]
33. Serpins: finely balanced conformational traps.
Pike RN; Bottomley SP; Irving JA; Bird PI; Whisstock JC
IUBMB Life; 2002 Jul; 54(1):1-7. PubMed ID: 12387568
[TBL] [Abstract][Full Text] [Related]
34. Mammary serine protease inhibitor inhibits epithelial growth factor-induced epithelial-mesenchymal transition of esophageal carcinoma cells.
Cai Z; Zhou Y; Lei T; Chiu JF; He QY
Cancer; 2009 Jan; 115(1):36-48. PubMed ID: 19090015
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of maspin expression in human gastric adenocarcinoma.
Song SY; Son HJ; Kim MH; Nam ES; Rhee JC; Park C
Hepatogastroenterology; 2007; 54(75):973-6. PubMed ID: 17591106
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution--implications for serpin mechanistic model and prediction of nsSNP activities.
Di Giusto DA; Sutherland AP; Jankova L; Harrop SJ; Curmi PM; King GC
J Mol Biol; 2005 Nov; 353(5):1069-80. PubMed ID: 16214170
[TBL] [Abstract][Full Text] [Related]
37. Cytoplasmic antiproteinase 2 (PI8) and bomapin (PI10) map to the serpin cluster at 18q21.3.
Bartuski AJ; Kamachi Y; Schick C; Overhauser J; Silverman GA
Genomics; 1997 Aug; 43(3):321-8. PubMed ID: 9268635
[TBL] [Abstract][Full Text] [Related]
38. Expression of maspin in colorectal cancer.
Umekita Y; Souda M; Yoshida H
In Vivo; 2006; 20(6B):797-800. PubMed ID: 17203770
[TBL] [Abstract][Full Text] [Related]
39. Correlation of serpin-protease expression by comparative analysis of real-time PCR profiling data.
Badola S; Spurling H; Robison K; Fedyk ER; Silverman GA; Strayle J; Kapeller R; Tsu CA
Genomics; 2006 Aug; 88(2):173-84. PubMed ID: 16713170
[TBL] [Abstract][Full Text] [Related]
40. Maspin binds to urokinase-type and tissue-type plasminogen activator through exosite-exosite interactions.
Al-Ayyoubi M; Schwartz BS; Gettins PG
J Biol Chem; 2007 Jul; 282(27):19502-9. PubMed ID: 17510061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
